X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/10/2895960/0/en/MoonLake-Immunotherapeutics-Announces-Positive-Regulatory-Feedback-from-both-FDA-and-EMA-on-Path-for-the-Phase-3-Program-for-the-Nanobody-sonelokimab-in-Psoriatic-Arthritis.html
https://www.globenewswire.com/news-release/2024/05/16/2883358/0/en/MoonLake-Immunotherapeutics-starts-Phase-3-VELA-program-of-the-Nanobody-sonelokimab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa.html
https://www.globenewswire.com/news-release/2024/05/07/2876640/0/en/MoonLake-Immunotherapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/10/2860628/0/en/MoonLake-Immunotherapeutics-inks-three-year-technology-partnership-with-Komodo-Health-to-advance-research-on-inflammatory-skin-and-joint-conditions.html
https://endpts.com/moonlake-outlines-more-data-in-psoriatic-arthritis-as-it-preps-for-pivotal-trials-aad24/
https://www.globenewswire.com/news-release/2024/03/10/2843427/0/en/MoonLake-announces-significant-improvements-with-Nanobody-sonelokimab-over-24-weeks-in-active-psoriatic-arthritis-PsA-and-other-important-updates-at-its-R-D-Day.html
https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-reports-full-year-2023-financial
https://www.globenewswire.com//news-release/2024/02/26/2835058/0/en/MoonLake-Immunotherapeutics-Announces-Positive-Feedback-from-both-FDA-and-EMA-on-Regulatory-Path-for-the-Phase-3-Program-of-the-Nanobody-sonelokimab-SLK-in-Hidradenitis-Suppurativa.html
https://finance.yahoo.com/news/insider-sell-ceo-santos-da-044423293.html
https://www.globenewswire.com//news-release/2023/11/14/2780026/0/en/MoonLake-Immunotherapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html
Market Place
Share 
